BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Multidimensional Immunoengineering Approaches to Enhanced Cancer I
 mmunotherapy
DTSTART:20220309T100000
DTEND:20220309T110000
DTSTAMP:20260407T064129Z
UID:8d03b19da2ef5eb01afb9d88566dde8c8da4a174c0eaa3560540ff0a
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Li Tang\, Institute of Bioengineering and Institute of M
 aterials\, School of Engineering\, EPFL\, Lausanne (CH)\nBIOENGINEERING SE
 MINAR\n\nAbstract:\nOur immune system constantly interacts with invading p
 athogens and diseased cells in a multidimensional manner involving substan
 tial biological\, chemical\, and physical exchanges. Manipulating the dise
 ase-immunity interactions may afford novel immunotherapies to better treat
  many diseases. My lab aims to develop novel strategies to engineer the mu
 ltidimensional immunity-disease interactions (or termed ‘immunoengineeri
 ng’) to create safe and effective immunotherapy against cancer. We lever
 age the power of metabolic and cellular bioengineering\, synthetic chemist
 ry and material engineering\, and mechanical engineering to achieve contro
 llable modulation of immune responses. In this talk\, I will first descri
 be our discovery of a new type of immune checkpoint with mechanical basis\
 , which is distinct from known immune checkpoints of biochemical traits. W
 e further developed a mechanical intervention to overcome the mechanical i
 mmune checkpoint for enhanced cancer immunotherapy. In the second part of 
 my talk\, I will share our recent discovery of IL-10-Fc as a metabolic rep
 rogramming agent that reinvigorates the terminally exhausted CD8+ tumor in
 filtrating lymphocytes and sustains their cytotoxic functions leading to e
 radication of established solid tumors and durable cures in a majority of 
 treated mice when combined with adoptive T-cell transfer immunotherapies. 
 Finally\, I will briefly talk about our efforts in chemical immunoengineer
 ing and vision for future research.\n\nBio:\nLi Tang received his B.S. in 
 Chemistry from Peking University\, China\, in 2007\, and Ph.D. in Material
 s Science and Engineering from University of Illinois at Urbana-Champaign\
 , USA\, in 2012\, under the supervision of Prof. Jianjun Cheng. He was an 
 CRI Irvington Postdoctoral Fellow in the laboratory of Prof. Darrell Irvin
 e at Massachusetts Institute of Technology during 2013-2016. He joined the
  faculty of Institute of Bioengineering\, and Institute of Materials Scien
 ce & Engineering\, at École polytechnique fédérale de Lausanne (EPFL)\,
  Switzerland\, as a Tenure-Track Assistant Professor since 2016. His resea
 rch focuses on developing multidimensional immunoengineering approaches 
 to enhanced cancer immunotherapies. Dr. Tang is the recipient of Cancer Re
 search Institute CLIP Award (2021)\, Anna Fuller Award (2021 and 2022)\, a
 nd named in the MIT Technology Review’s "Top 35 Innovators under Age 35"
  list of China region (2020)\, Materials Horizons Emerging Investigator (2
 020)\, Biomaterials Science Emerging Investigator (2019)\, recipient of Eu
 ropean Research Council (ERC) starting grant (2018)\, and Nano Research Yo
 ung Innovator Award (NR 45 under 45) (2018).\n.\n\nZoom link for attending
  remotely: https://epfl.zoom.us/j/65122053638\n\n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717 https://epfl.zoom.u
 s/j/65122053638
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR